

DR REDDYS LABORATORIES LTD

Form 6-K

September 14, 2004

**Table of Contents**

---

---

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**For the month of August, 2004**

**Commission File Number 1-15182**

**DR. REDDY S LABORATORIES LIMITED**

(Name of Registrant)

**7-1-27, Ameerpet  
Hyderabad, Andhra Pradesh 500 016, India  
+91-40-23731946**

---

(Address of Principal Executive Offices)

Indicate by check mark whether registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b):

Not applicable.

---

---

---

**TABLE OF CONTENTS**

Press Release  
Signatures

---

**Table of Contents**

**Table of Contents**

(1) Press Release, Dr. Reddy s launches cream for treating dry skin conditions, August 12, 2004.

2

---

**Table of Contents**

Dr. Reddy s Laboratories Ltd.  
7-1-27 Ameerpet  
Hyderabad 500 016 India

Tel: 91 40 2373 1946  
Fax: 91 40 2373 1955

www.drreddys.com

**Dr. Reddy s launches cream for treating dry skin conditions.**

Hyderabad, India, August 12, 2004:

Venusia, a skin moisturizing cream indicated for the treatment of dry skin conditions, has been launched by Dr. Reddy s Laboratories as part of its portfolio of dermatology products. Venusia, which is available in 50g jars, is a prescription product.

Venusia combines the advantages of squalene, an ingredient introduced for the first time in India, with the conventional healing power of aloe vera and anti-oxidant properties of vitamin E. Squalene is a part of sebum, which is body s own natural moisturiser. Venusia is non-greasy and can be applied easily over the skin.

Dr. Reddy s has a total of eight brands in the dermatology segment in the Indian market with sales of Rs.23 crore in the last fiscal year and a growth rate of 27 per cent. The leading brands in this segment for Dr. Reddy s include Mintop, Mintop Forte, Gris OD and Antoxid HC.

Clearz, an ointment for treating hyperpigmentation, is another brand in this segment and was launched recently. Clearz combines Kojic Acid and Vitamin C. Dr. Reddy s was the first company in India to launch a product with this combination.

**About Dr. Reddy s**

Established in 1984, Dr. Reddy s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection.

**Table of Contents**

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

Contact Information

Media: Pratap Antony at [pratapa@drreddys.com](mailto:pratapa@drreddys.com) or on +91-40-55511634 or R Rammohan at [rammohanr@drreddys.com](mailto:rammohanr@drreddys.com) or on +91-40-55511620.

Investors and Financial Analysts: Nikhil Shah at [nikhilshah@drreddys.com](mailto:nikhilshah@drreddys.com) or on +91-40-55511532

**Table of Contents**

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Dr. Reddy s Laboratories Limited**

\_\_\_\_\_  
(Registrant)

Date: September 14, 2004

By: \_\_\_\_\_ /s/ V. Viswanath

\_\_\_\_\_  
(Signature)\*  
**V. Viswanath**  
**Company Secretary**

\* Print the name and title of the signing officer under his signature.